292 related articles for article (PubMed ID: 7884863)
1. Antiviral protection by vesicular stomatitis virus-specific antibodies in alpha/beta interferon receptor-deficient mice.
Steinhoff U; Müller U; Schertler A; Hengartner H; Aguet M; Zinkernagel RM
J Virol; 1995 Apr; 69(4):2153-8. PubMed ID: 7884863
[TBL] [Abstract][Full Text] [Related]
2. CD4(+) T cell subsets during virus infection. Protective capacity depends on effector cytokine secretion and on migratory capability.
Maloy KJ; Burkhart C; Junt TM; Odermatt B; Oxenius A; Piali L; Zinkernagel RM; Hengartner H
J Exp Med; 2000 Jun; 191(12):2159-70. PubMed ID: 10859340
[TBL] [Abstract][Full Text] [Related]
3. Monovalent single-chain Fv fragments and bivalent miniantibodies bound to vesicular stomatitis virus protect against lethal infection.
Kalinke U; Krebber A; Krebber C; Bucher E; Plückthun A; Zinkernagel RM; Hengartner H
Eur J Immunol; 1996 Dec; 26(12):2801-6. PubMed ID: 8977271
[TBL] [Abstract][Full Text] [Related]
4. Concomitant TLR/RLH signaling of radioresistant and radiosensitive cells is essential for protection against vesicular stomatitis virus infection.
Spanier J; Lienenklaus S; Paijo J; Kessler A; Borst K; Heindorf S; Baker DP; Kröger A; Weiss S; Detje CN; Staeheli P; Kalinke U
J Immunol; 2014 Sep; 193(6):3045-54. PubMed ID: 25127863
[TBL] [Abstract][Full Text] [Related]
5. The role of antibody concentration and avidity in antiviral protection.
Bachmann MF; Kalinke U; Althage A; Freer G; Burkhart C; Roost H; Aguet M; Hengartner H; Zinkernagel RM
Science; 1997 Jun; 276(5321):2024-7. PubMed ID: 9197261
[TBL] [Abstract][Full Text] [Related]
6. Matrix protein mediated shutdown of host cell metabolism limits vesicular stomatitis virus-induced interferon-alpha responses to plasmacytoid dendritic cells.
Waibler Z; Detje CN; Bell JC; Kalinke U
Immunobiology; 2007; 212(9-10):887-94. PubMed ID: 18086387
[TBL] [Abstract][Full Text] [Related]
7. Vesicular stomatitis virus glycoprotein displaying retrovirus-like particles induce a type I IFN receptor-dependent switch to neutralizing IgG antibodies.
Bach P; Kamphuis E; Odermatt B; Sutter G; Buchholz CJ; Kalinke U
J Immunol; 2007 May; 178(9):5839-47. PubMed ID: 17442968
[TBL] [Abstract][Full Text] [Related]
8. The role of antibodies in natural and acquired resistance of mice to vesicular stomatitis virus.
Gobet R; Cerny A; Rüedi E; Hengartner H; Zinkernagel RM
Exp Cell Biol; 1988; 56(4):175-80. PubMed ID: 2849570
[TBL] [Abstract][Full Text] [Related]
9. Chimeric measles viruses with a foreign envelope.
Spielhofer P; Bächi T; Fehr T; Christiansen G; Cattaneo R; Kaelin K; Billeter MA; Naim HY
J Virol; 1998 Mar; 72(3):2150-9. PubMed ID: 9499071
[TBL] [Abstract][Full Text] [Related]
10. Subcapsular sinus macrophages prevent CNS invasion on peripheral infection with a neurotropic virus.
Iannacone M; Moseman EA; Tonti E; Bosurgi L; Junt T; Henrickson SE; Whelan SP; Guidotti LG; von Andrian UH
Nature; 2010 Jun; 465(7301):1079-83. PubMed ID: 20577213
[TBL] [Abstract][Full Text] [Related]
11. Xenoantigen-Dependent Complement-Mediated Neutralization of Lymphocytic Choriomeningitis Virus Glycoprotein-Pseudotyped Vesicular Stomatitis Virus in Human Serum.
Pipperger L; Koske I; Wild N; Müllauer B; Krenn D; Stoiber H; Wollmann G; Kimpel J; von Laer D; Bánki Z
J Virol; 2019 Sep; 93(18):. PubMed ID: 31243134
[TBL] [Abstract][Full Text] [Related]
12. Qualitative and quantitative requirements for CD4+ T cell-mediated antiviral protection.
Maloy KJ; Burkhart C; Freer G; Rülicke T; Pircher H; Kono DH; Theofilopoulos AN; Ludewig B; Hoffmann-Rohrer U; Zinkernagel RM; Hengartner H
J Immunol; 1999 Mar; 162(5):2867-74. PubMed ID: 10072535
[TBL] [Abstract][Full Text] [Related]
13. Superantigen-activated T cells redirected by a bispecific antibody inhibit vesicular stomatitis virus replication in vitro and in vivo.
Fernandez-Sesma A; Peluso RW; Bai X; Schulman JL; Levy DE; Moran TM
J Immunol; 1998 Feb; 160(4):1841-9. PubMed ID: 9469445
[TBL] [Abstract][Full Text] [Related]
14. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity.
Obuchi M; Fernandez M; Barber GN
J Virol; 2003 Aug; 77(16):8843-56. PubMed ID: 12885903
[TBL] [Abstract][Full Text] [Related]
15. Protective efficacy of a recombinant Newcastle disease virus expressing glycoprotein of vesicular stomatitis virus in mice.
Zhang M; Ge J; Li X; Chen W; Wang X; Wen Z; Bu Z
Virol J; 2016 Feb; 13():31. PubMed ID: 26911572
[TBL] [Abstract][Full Text] [Related]
16. Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein.
Fukushi S; Mizutani T; Saijo M; Matsuyama S; Miyajima N; Taguchi F; Itamura S; Kurane I; Morikawa S
J Gen Virol; 2005 Aug; 86(Pt 8):2269-2274. PubMed ID: 16033974
[TBL] [Abstract][Full Text] [Related]
17. VSV replication in neurons is inhibited by type I IFN at multiple stages of infection.
Trottier MD; Palian BM; Reiss CS
Virology; 2005 Mar; 333(2):215-25. PubMed ID: 15721356
[TBL] [Abstract][Full Text] [Related]
18. A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection.
Foley HD; McGettigan JP; Siler CA; Dietzschold B; Schnell MJ
Proc Natl Acad Sci U S A; 2000 Dec; 97(26):14680-5. PubMed ID: 11114165
[TBL] [Abstract][Full Text] [Related]
19. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
[TBL] [Abstract][Full Text] [Related]
20. Vesicular stomatitis virus Indiana glycoprotein as a T-cell-dependent and -independent antigen.
Freer G; Burkhart C; Ciernik I; Bachmann MF; Hengartner H; Zinkernagel RM
J Virol; 1994 Jun; 68(6):3650-5. PubMed ID: 7910641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
